[go: up one dir, main page]

BR0308696A - Derivados de quinolina e seu emprego como ligante de 5-ht6 - Google Patents

Derivados de quinolina e seu emprego como ligante de 5-ht6

Info

Publication number
BR0308696A
BR0308696A BR0308696-8A BR0308696A BR0308696A BR 0308696 A BR0308696 A BR 0308696A BR 0308696 A BR0308696 A BR 0308696A BR 0308696 A BR0308696 A BR 0308696A
Authority
BR
Brazil
Prior art keywords
group
independently represent
binder
integer
quinoline derivatives
Prior art date
Application number
BR0308696-8A
Other languages
English (en)
Other versions
BRPI0308696B1 (pt
BRPI0308696B8 (pt
BRPI0308696A8 (pt
Inventor
Mahmood Ahmed
Christopher Norbert Johnson
Martin C Jones
Gregor James Macdonald
Stephen Frederick Moss
Mervyn Thompson
Charles Edward Wade
David Witty
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28456035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0308696(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0207289A external-priority patent/GB0207289D0/en
Priority claimed from GB0225678A external-priority patent/GB0225678D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR0308696A publication Critical patent/BR0308696A/pt
Publication of BRPI0308696A8 publication Critical patent/BRPI0308696A8/pt
Publication of BRPI0308696B1 publication Critical patent/BRPI0308696B1/pt
Publication of BRPI0308696B8 publication Critical patent/BRPI0308696B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE QUINOLINA E SEU EMPREGO COMO LIGANTE DE 5-HT~ 6~". A presente invenção se refere a compostos de quinolina da fórmula (I) ou a um sal farmaceuticamente aceitável seu, em que R^ 1^ e R^ 2^ representam independentemente hidrogênio ou alquila C~ 1-6~ ou então R^ 1^ é ligado a R^ 2^ para formar um grupo (CH~ 2~ )~ 2~, (CH~ 2~)~ 3~ ou (CH~ 2~)~ 4~; R^ 3^, R^ 4^ e R^ 5^ representam independentemente hidrogênio, halogênio, ciano, -CF~ 3~ -CF~ 3~O, alquila C~ 1-6~, alcóxi C~ 1-6~, alcanoíla C~ 1-6~ ou um grupo -CONR^ 6^ R^ 7^ ; m representa um número inteiro de 1 a 4, de modo tal que quando m for um número inteiro maior do que 1, dois grupos R^ 2^ podem em vez disso ser ligados entre si para formar um grupo CH~ 2~, (CH~ 2~)~ 2~ ou (CH~ 2~)~ 3~; n representa um número inteiro de 1 a 3; p representa 1 ou 2; A representa um grupo -Ar^ 1^ ou -Ar^ 2^ Ar^ 3^; Ar~ 1^, Ar^ 2^ e Ar^ 3^ representam independentemente um grupo arila ou um grupo heteroarila, podendo ambos ser opcionalmente substituídos por um ou mais substituintes que tem atividade farmacológica, a processos para a sua preparação, a composições contendo-os e a seu emprego no tratamento de distúrbios do SNC e outros.
BRPI0308696A 2002-03-27 2003-03-25 composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos BRPI0308696B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0207289.0 2002-03-27
GB0207289A GB0207289D0 (en) 2002-03-27 2002-03-27 Novel compounds
GB0225678A GB0225678D0 (en) 2002-11-04 2002-11-04 Novel compounds
GB0225678.2 2002-11-04
PCT/EP2003/003197 WO2003080580A2 (en) 2002-03-27 2003-03-25 Quinoline derivatives and their use as 5-ht6 ligands

Publications (4)

Publication Number Publication Date
BR0308696A true BR0308696A (pt) 2005-01-25
BRPI0308696A8 BRPI0308696A8 (pt) 2017-04-11
BRPI0308696B1 BRPI0308696B1 (pt) 2019-07-16
BRPI0308696B8 BRPI0308696B8 (pt) 2021-05-25

Family

ID=28456035

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0308696A BRPI0308696B8 (pt) 2002-03-27 2003-03-25 composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos

Country Status (28)

Country Link
US (5) US7452888B2 (pt)
EP (2) EP1956004B1 (pt)
JP (2) JP4455064B2 (pt)
KR (1) KR101020399B1 (pt)
CN (1) CN1315809C (pt)
AR (1) AR039127A1 (pt)
AT (1) ATE398108T1 (pt)
AU (1) AU2003219103B2 (pt)
BR (1) BRPI0308696B8 (pt)
CA (1) CA2479786C (pt)
CY (2) CY1108313T1 (pt)
DE (1) DE60321558D1 (pt)
DK (2) DK1497266T3 (pt)
ES (2) ES2386828T3 (pt)
HK (1) HK1074439A1 (pt)
IL (2) IL164108A0 (pt)
IS (1) IS2599B (pt)
MX (1) MXPA04009318A (pt)
MY (1) MY138836A (pt)
NO (1) NO329319B1 (pt)
NZ (1) NZ535239A (pt)
PL (1) PL209872B1 (pt)
PT (2) PT1956004E (pt)
RU (1) RU2309154C9 (pt)
SI (2) SI1956004T1 (pt)
TW (1) TWI268928B (pt)
WO (1) WO2003080580A2 (pt)
ZA (1) ZA200407320B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1315809C (zh) * 2002-03-27 2007-05-16 葛兰素集团有限公司 喹啉衍生物和其作为5－ht6配体的用途
EP1592690A1 (en) 2003-02-14 2005-11-09 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
KR20050101551A (ko) 2003-02-14 2005-10-24 와이어쓰 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴-3-설포닐인다졸
RS20060035A (en) 2003-07-22 2008-08-07 Arena Pharmaceuticals Inc., Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
GB0320320D0 (en) * 2003-08-29 2003-10-01 Glaxo Group Ltd Novel compounds
GB0321473D0 (en) 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0322510D0 (en) 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
PT1667975E (pt) * 2003-09-26 2008-02-29 Glaxo Group Ltd Forma polimórfica de 3-fenilsulfonil-8-piperazin-1-il-quinolina
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
GB0425548D0 (en) * 2004-11-19 2004-12-22 Glaxo Group Ltd Radiolabelled ligands
GB0426313D0 (en) * 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
MX2007014929A (es) 2005-06-02 2008-02-15 Hoffmann La Roche 3-metansulfonilquinolinas como mejoradores de gaba-b.
EP1910296B1 (en) 2005-07-27 2010-04-21 F.Hoffmann-La Roche Ag 4-aryloxy quinoline derivatives as 5-ht6 modulators
GB0519758D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel process
GB0519765D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
GB0519760D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
EP1962849B1 (en) * 2005-12-20 2009-09-30 Richter Gedeon NYRT Quinoline derivatives useful in the treatment of mglur5 receptor-mediated disorders
MX2008012824A (es) 2006-04-05 2008-10-15 Wyeth Corp Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6.
JP2010515674A (ja) 2007-01-08 2010-05-13 スベン ライフ サイエンシズ リミティド ５−（ヘテロシクリル）アルキル−ｎ−（アリールスルホニル）インドール化合物および５−ｈｔ６リガンドとしてのそれらの使用
EP2137162B1 (en) * 2007-03-15 2018-08-01 Novartis AG Organic compounds and their uses
US20100041672A1 (en) * 2007-03-21 2010-02-18 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
WO2008116831A1 (en) 2007-03-23 2008-10-02 Abbott Gmbh & Co. Kg Quinoline compounds suitable for treating didorders that respond to modulation of the serotonin 5-ht6 receptor
WO2008136017A1 (en) 2007-05-03 2008-11-13 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
JP5543917B2 (ja) * 2007-06-18 2014-07-09 リヒター ゲデオン ニルバーノシャン ミーケデーレスベニュタールシャシャーグ スルホニル−キノリン誘導体
CN101687866B (zh) * 2007-08-07 2014-06-04 Abbvie德国有限责任两合公司 用于治疗响应于血色素5-ht6受体调节的疾病的喹啉化合物
MX2010003765A (es) 2007-10-26 2010-04-30 Suven Life Sciences Ltd Compuestos de aminoarilsulfonamida y su uso como ligandos de la 5-hidroxitriptamina6.
EP2254564A1 (en) * 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
KR20100101171A (ko) * 2008-02-15 2010-09-16 에프. 호프만-라 로슈 아게 3-알킬-피페라진 유도체 및 이의 용도
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
EA019496B1 (ru) 2008-09-17 2014-04-30 Сувен Лайф Сайенсиз Лимитед Арилсульфонамидные аминосоединения и их применение в качестве лигандов 5-ht
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
BRPI1011587B1 (pt) * 2009-06-29 2020-03-24 Agios Pharmaceuticals, Inc. Compostos de quinolina sulfonamida com atividade moduladora de pmk2 e uso dos mesmos
CU24144B1 (es) * 2010-01-04 2016-01-29 Nippon Soda Co Compuesto heterocíclico conteniendo nitrógeno y fungicida para el uso en agricultura y jardinería
KR101463190B1 (ko) 2010-01-05 2014-11-18 수벤 라이프 사이언시스 리미티드 ５­ｈｔ６ 수용체 리간드인 술폰 화합물
RU2443697C1 (ru) * 2010-12-21 2012-02-27 Александр Васильевич Иващенко Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения
KR101250606B1 (ko) * 2011-01-24 2013-04-03 이화여자대학교 산학협력단 5-ｈｔ６ 수용체 억제 작용을 갖는 신규한 벤조티아졸 및 벤즈이소티아졸유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
AR086411A1 (es) 2011-05-20 2013-12-11 Nippon Soda Co Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria
CA2850707C (en) 2011-10-03 2023-03-21 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
RU2500672C1 (ru) * 2012-10-25 2013-12-10 Андрей Александрович Иващенко (3-арилсульфонилхинолин-8-ил)-диалкил-амины - селективные антагонисты серотониновых 5-ht6 рецепторов, способы их получения и применения
CN105452224B (zh) 2013-04-02 2017-12-26 安基生技新药股份有限公司 作为抗神经退化剂的多官能性喹啉衍生物
US9302992B2 (en) 2013-04-02 2016-04-05 Annji Pharmaceutical Co., Ltd. Multifunctional quinoline derivatives as anti-neurodegenerative agents
MX2017014192A (es) * 2015-05-07 2018-08-01 Axovant Sciences Gmbh Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
WO2016201373A1 (en) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
KR20180064373A (ko) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
AR106515A1 (es) * 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
AU2017216288B2 (en) * 2016-02-05 2022-06-02 Pharnext Novel combinatorial therapies of neurological disorders
WO2017157929A1 (en) * 2016-03-14 2017-09-21 AbbVie Deutschland GmbH & Co. KG Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
CN108290842B (zh) * 2016-05-27 2021-04-06 深圳市塔吉瑞生物医药有限公司 一种取代的喹啉化合物及其药物组合物
WO2018102824A1 (en) * 2016-12-02 2018-06-07 Axovant Sciences Gmbh Methods for treating neurodegenerative disease
KR20210076224A (ko) 2019-12-13 2021-06-24 주식회사 에피바이오텍 퀴놀린 유도체를 포함하는 탈모의 예방 또는 치료용 조성물
KR102281647B1 (ko) * 2020-12-09 2021-07-30 메디케어제약 주식회사 피페라진-퀴놀린 유도체의 제조방법

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US708469A (en) * 1901-08-27 1902-09-02 George Lafayette Caldwell Stroke-regulating mechanism for glass-presses, &c.
JPH02262627A (ja) 1988-12-08 1990-10-25 Japan Synthetic Rubber Co Ltd 有機非線形光学素子
SI9200377A (en) * 1992-12-11 1994-06-30 Krka Process for the preparation of 1-substituted 6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydroquinoline-3-carboxilic acid, novel intermediate used in this process and process for its preparation
GB9300147D0 (en) 1993-01-06 1993-03-03 Minnesota Mining & Mfg Photothermographic materials
GB9311790D0 (en) 1993-06-08 1993-07-28 Minnesota Mining & Mfg Photothermographic materials
US5596001A (en) * 1993-10-25 1997-01-21 Pfizer Inc. 4-aryl-3-(heteroarylureido)quinoline derivatves
DK122693D0 (da) 1993-10-29 1993-10-29 Hempels Skibsfarve Fab J C Marin struktur
US5576338A (en) 1995-02-15 1996-11-19 Merck Frosst Canada, Inc. Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
AUPN842196A0 (en) 1996-03-05 1996-03-28 Fujisawa Pharmaceutical Co., Ltd. New compound
FR2750988B1 (fr) 1996-07-11 1998-09-18 Adir Nouveaux derives de 2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20010051719A1 (en) * 1996-12-19 2001-12-13 Smithkline Beecham P.L.C. Novel compounds
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
DE59803962D1 (de) 1997-03-25 2002-06-06 Ciba Sc Holding Ag Polycyclische Verbindungen
WO1998047874A1 (en) 1997-04-22 1998-10-29 Janssen Pharmaceutica N.V. Crf antagonistic quino- and quinazolines
ES2235331T3 (es) 1997-05-28 2005-07-01 Aventis Pharmaceuticals Inc Compuestos quinolina y quinoxalina que inhiben el factor de crecimiento derivado de plaquetas y/o tirosina quinasas p561ck.
US6376670B1 (en) * 1997-06-19 2002-04-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
AU757059B2 (en) * 1997-06-19 2003-01-30 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6207679B1 (en) 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
US6103905A (en) 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
KR20010021643A (ko) 1997-07-11 2001-03-15 피터 기딩스 5-ｈｔ6수용체길항제인술폰아미드유도체및그의제조방법
ES2193607T3 (es) * 1998-01-16 2003-11-01 Hoffmann La Roche Derivados de benzosulfona .
GB9801392D0 (en) * 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6100291A (en) 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
US6403808B1 (en) * 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
EP1147094A1 (en) 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
WO2000058313A1 (en) 1999-03-29 2000-10-05 Neurogen Corporation 4-substituted quinoline derivatives as gaba receptor ligands
AU778682B2 (en) * 1999-04-21 2004-12-16 Nps Pharmaceuticals, Inc. Piperidine-indole compounds having 5-HT6 affinity
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
WO2001032660A1 (en) 1999-11-05 2001-05-10 Nps Allelix Corp. Compounds having 5-ht6 receptor antagonist activity
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US6310212B1 (en) * 2000-03-28 2001-10-30 Neurogen Corporation 4-substituted quinoline derivatives
PE20020063A1 (es) 2000-06-20 2002-01-30 Upjohn Co Bis-arilsulfonas como ligandos del receptor de 5-ht
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
GB0021450D0 (en) 2000-08-31 2000-10-18 Smithkline Beecham Plc Novel compounds
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
JP2004510764A (ja) 2000-10-02 2004-04-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 代謝共役型グルタミン酸受容体拮抗剤
EP1326830A1 (en) 2000-10-20 2003-07-16 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
CA2426031C (en) 2000-11-02 2011-10-04 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
JP2004517826A (ja) 2000-11-21 2004-06-17 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Ｃｎｓ障害の治療において有用なイソキノリン誘導体
DE60122767T2 (de) 2000-11-24 2007-09-13 Smithkline Beecham P.L.C., Brentford Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
ES2188344B1 (es) 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
MXPA03011244A (es) 2001-06-07 2004-02-27 Hoffmann La Roche Nuevos derivados de indol con afinidad por el receptor 5-ht6.
MXPA03011638A (es) 2001-06-15 2004-04-02 Hoffmann La Roche Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
ITRM20010356A1 (it) * 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
CA2452743A1 (en) 2001-08-03 2003-02-13 Pharmacia & Upjohn Company 5-arylsulfonyl indoles having 5-ht6 receptor affinity
EP1414442A1 (en) 2001-08-07 2004-05-06 Smithkline Beecham Plc 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
PL373397A1 (en) 2001-08-10 2005-08-22 F.Hoffmann-La Roche Ag Arylsulfonyl derivatives with 5-ht6 receptor affinity
DK1425272T3 (da) 2001-08-31 2011-11-21 Novartis Ag Optiske isomerer af en iloperidon-metabolit
SE0103649D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
US20050176759A1 (en) 2001-12-21 2005-08-11 Mahmood Ahmed 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
EP1471912A1 (en) 2002-02-05 2004-11-03 Glaxo Group Limited Method of promoting neuronal growth
EP1487801B1 (en) * 2002-02-13 2006-04-19 Glaxo Group Limited 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo¬d|azepine derivatives with 5-ht6 receptor affinity for the treatment of cns disorders
DE10207844A1 (de) 2002-02-15 2003-09-04 Schering Ag 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
CA2476173A1 (en) 2002-02-22 2003-09-04 Ruth E. Tenbrink Arylsulfone derivatives
CN1315809C (zh) * 2002-03-27 2007-05-16 葛兰素集团有限公司 喹啉衍生物和其作为5－ht6配体的用途
ES2277098T3 (es) 2002-03-27 2007-07-01 Glaxo Group Limited Derivados de quinolina y aza-indol y su uso como ligandos para 5-ht6.
DE10221183A1 (de) 2002-05-13 2003-12-04 Max Planck Gesellschaft Phosphatidyl-oligo-glycerine und Strukturanaloga
ES2256744T3 (es) 2002-05-13 2006-07-16 F. Hoffmann-La Roche Ag Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos.
BR0311593A (pt) 2002-06-05 2005-04-26 Hoffmann La Roche Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores de receptor 5-ht6 para tratamento dos distúrbios de snc
US7943639B2 (en) * 2002-06-20 2011-05-17 Proximagen Limited Compounds
NZ552283A (en) 2002-06-20 2008-07-31 Biovitrum Ab Publ New compounds useful for the treatment of obesity, type II diabetes and CNS disorders
WO2004026830A1 (en) 2002-09-17 2004-04-01 F. Hoffmann-La Roche Ag 2,7-substituted indoles and their use as 5-ht6 modulators
JP4267573B2 (ja) 2002-09-17 2009-05-27 エフ．ホフマン−ラ ロシュ アーゲー ２，４−置換インドールおよびそれらの５−ｈｔ６モジュレーターとしての使用
MXPA05004128A (es) 2002-10-18 2005-06-22 Hoffmann La Roche 4-piperazinil bencenosulfonil indoles con afinidad al receptor 5-hidroxitriptamina 6 (5-ht6).
CN100390157C (zh) 2002-11-08 2008-05-28 弗·哈夫曼-拉罗切有限公司 取代的苯并嗪酮及其用途
WO2004050085A1 (en) * 2002-12-03 2004-06-17 F. Hoffmann-La Roche Ag Aminoalkoxyindoles as 5-ht6-receptor ligands for the treatment of cns-disorders
EP1592690A1 (en) * 2003-02-14 2005-11-09 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
MXPA05009359A (es) 2003-03-03 2005-11-04 Hoffmann La Roche Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6.
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
TWI289141B (en) 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
GB0320320D0 (en) 2003-08-29 2003-10-01 Glaxo Group Ltd Novel compounds
GB0321473D0 (en) 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0322510D0 (en) 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
PT1667975E (pt) 2003-09-26 2008-02-29 Glaxo Group Ltd Forma polimórfica de 3-fenilsulfonil-8-piperazin-1-il-quinolina
GB0407025D0 (en) 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
GB0411421D0 (en) 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
GB0422263D0 (en) 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
GB0519765D0 (en) 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
GB0519760D0 (en) 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
US8236947B2 (en) 2012-08-07
JP5091913B2 (ja) 2012-12-05
NO329319B1 (no) 2010-09-27
NZ535239A (en) 2008-03-28
EP1497266A2 (en) 2005-01-19
KR20040094874A (ko) 2004-11-10
BRPI0308696B1 (pt) 2019-07-16
PT1956004E (pt) 2012-08-31
US20050124628A1 (en) 2005-06-09
CY1108313T1 (el) 2014-02-12
DK1956004T3 (da) 2012-08-06
PT1497266E (pt) 2008-09-10
US7799774B2 (en) 2010-09-21
BRPI0308696B8 (pt) 2021-05-25
IS7470A (is) 2004-09-24
IL164108A (en) 2010-05-31
AU2003219103A1 (en) 2003-10-08
US20100305107A1 (en) 2010-12-02
US7601837B2 (en) 2009-10-13
CA2479786A1 (en) 2003-10-02
CY1113306T1 (el) 2016-04-13
DK1497266T3 (da) 2008-10-06
EP1497266B1 (en) 2008-06-11
CA2479786C (en) 2011-11-29
EP1956004A1 (en) 2008-08-13
WO2003080580A2 (en) 2003-10-02
RU2309154C9 (ru) 2016-09-27
RU2004131641A (ru) 2005-06-27
RU2309154C2 (ru) 2007-10-27
JP2005531518A (ja) 2005-10-20
US20090298841A1 (en) 2009-12-03
KR101020399B1 (ko) 2011-03-08
IL164108A0 (en) 2005-12-18
US20090036682A1 (en) 2009-02-05
ES2307919T3 (es) 2008-12-01
SI1956004T1 (sl) 2012-09-28
PL209872B1 (pl) 2011-10-31
TW200403224A (en) 2004-03-01
MXPA04009318A (es) 2005-01-25
CN1656075A (zh) 2005-08-17
TWI268928B (en) 2006-12-21
MY138836A (en) 2009-07-31
ES2386828T3 (es) 2012-08-31
PL374378A1 (en) 2005-10-17
AU2003219103B2 (en) 2008-10-23
SI1497266T1 (sl) 2008-10-31
US20110237792A1 (en) 2011-09-29
AR039127A1 (es) 2005-02-09
US7452888B2 (en) 2008-11-18
US7977337B2 (en) 2011-07-12
IS2599B (is) 2010-04-15
NO20044588L (no) 2004-10-25
BRPI0308696A8 (pt) 2017-04-11
HK1074439A1 (en) 2005-11-11
DE60321558D1 (de) 2008-07-24
JP2009235080A (ja) 2009-10-15
CN1315809C (zh) 2007-05-16
ZA200407320B (en) 2005-11-30
ATE398108T1 (de) 2008-07-15
EP1956004B1 (en) 2012-06-13
WO2003080580A3 (en) 2004-02-05
JP4455064B2 (ja) 2010-04-21

Similar Documents

Publication Publication Date Title
BR0308696A (pt) Derivados de quinolina e seu emprego como ligante de 5-ht6
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
HRP20040824B1 (hr) Derivati aminoindazola, postupak i međuprodukti dobiveni prilikom pripravljanja medicinskih produkata, te farmaceutski pripravci koji ih sadrže
TW200833675A (en) Nicotinamide derivatives
BRPI0616799B8 (pt) derivado de piridina e derivado de pirimidina, composições farmacêuticas, usos, inibidores de angiogênese, contra receptor de fator de crescimento de hepatócito e contra metástase de câncer, e agente antitumor
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
BRPI0519794A2 (pt) derivados de [4-(heteroaril)piperazin-1-il]-(fenil 2,5-substituìdo)metanona como inibidores de transportador de glicina 1 (glyt-1) para o tratamento de distúrbios neurológicos e neuropsiquiátricos
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
MX2007013021A (es) Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
CA2036876A1 (fr) Derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX2019012336A (es) Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos.
BR9912621A (pt) Derivado de ácido aminometilcarboxìlico, composição farmacêutica, e, uso de um derivado de ácido aminometilcarboxìlico
BRPI0408591A (pt) derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda
AR035427A1 (es) Compuestos derivados de piperidina, su empleo, un procedimiento para prepararlos y medicamentos que los contienen
ES482787A1 (es) Un procedimiento para preparar derivados de flavano, mono- di-y tri-sustituidos.
HUP0401883A2 (hu) Muszkarin agonisták és ezeket tartalmazó gyógyászati készítmények
RS51557B (en) 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS ALFA 7 NICOTINE ACETYLHOLINE RECEPTORS
ATE239711T1 (de) Neue allythiopyridazinderivate und verfahren zu ihrer herstellung
HUP0004704A2 (hu) Dihidrofuro[3,4-b]kinolin-1-on-származékok, eljárás ezek előállítására és ezeket tartalmazó gyógyászati készítmények
BRPI0415109A (pt) compostos de 1-[2-(4-hidroxifenil)-2-hidroxietil]-piperidin-4-ol como antagonistas de receptor de nmda
ES2099180T3 (es) Derivados del benzopirano y procedimientos para su preparacion.
HUP0302820A2 (hu) CNS rendellenességek kezelésében hasznos indolszármazékok és ezeket tartalmazó gyógyszerkészítmények
MX2023008250A (es) Compuestos de derivados sustituidos en 4,6 de ip4.
HUP0003856A2 (hu) 6-Pirrolidin-2-ilpirindin-származékok, eljárás előállításukra és gyógyászati alkalmazásuk

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: GLAXO GROUP LIMITED (GB)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: AXOVANT SCIENCES LTD (GB)

B25D Requested change of name of applicant approved

Owner name: AXOVANT SCIENCES LTD (GB)

B25D Requested change of name of applicant approved

Owner name: AXOVANT SCIENCES GMBH (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/03/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2663 DE 18-01-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.